Oncology Trials

In fit patients with newly diagnosed PCNSL who respond to MATRix induction, thiotepa-based HCT-ASCT consolidation nearly halved the risk of progression or death and yielded superior 3-year PFS (78% vs...

Adding biomarker-matched erlotinib, everolimus or dasatinib to radiotherapy did NOT improve overall survival in DIPG (median OS ~10–12 months across arms, no different from historical controls), but...

A single intratumoral injection of CAN-3110 produced deep and persistent T cell infiltration in recurrent GBM by locally expanding pre-existing tumor-infiltrating T cell clones; shorter average distan...

Adding low-dose WBRT (23.4 Gy) to R-MPV-A chemoimmunotherapy substantially improved 2-year PFS (78.7% vs 54%, HR 0.47, P=0.007) and complete response rates without producing measurable excess neurocog...

Monthly early palliative care did not significantly improve the primary FACT-Br Trial Outcome Index at 6 months, but produced consistent benefits in emotional well-being, palliative-care symptom burde...

Does intraoperative radiotherapy delivered to the resection cavity provide effective local control and acceptable safety in patients with newly diagnosed brain metastases?

In patients with 5 to 20 brain metastases, does stereotactic radiation targeting individual tumors reduce symptom burden and interference with daily function compared with hippocampal-avoidance whole brain radiation?

Can a CDK4/6 inhibitor shrink or stabilize progressive meningiomas harboring NF2 or CDK pathway mutations?

Does oncolytic herpes virus treatment reprogram the glioblastoma immune microenvironment to enable T cell-mediated tumor killing?

Oncolytic Virus for Recurrent Glioblastoma — Spatial Omics Analysis